Laurus Labs Acquires 60% Stake in Canada-Based Galenvs Sciences for USD 3.75 Million
Laurus Labs Ltd 路 Others (Uncategorized) 路 29 Oct 2026, 8:33 pm
Laurus Labs Acquires 60% Stake in Canada-Based Galenvs Sciences for USD 3.75 Million Laurus Labs' board approved acquiring a 60% stake in Canada-based CRO/CDMO Galenvs Sciences Inc. at a pre-money valuation of USD 3.50 million. The total cash investment of USD 3.75 million comprises a USD 2.75 million primary infusion (44% diluted stake) and a USD 1.00 million secondary purchase (16% diluted stake). Galenvs specializes in custom oligonucleotide synthesis and magnetic-nanoparticle technologies, clocking CY25 revenue of CAD 1.65 million. The deal bolsters Laurus Labs' oligonucleotide R&D pipeline and expands its North American footprint.
Original exchange filing (PDF)
More announcements from Laurus Labs Ltd
- Please see annexed enclosure. 路 18 Nov 2026
- Please see annexed enclosure. 路 11 Nov 2026
- Please see annexed enclosure. 路 03 Nov 2026
- Please see enclosed annexure. 路 30 Oct 2026
- Please see enclosed annexure 路 29 Oct 2026
- Please see enclosed annexure 路 29 Oct 2026
- Please see enclosed annexure 路 29 Oct 2026
- Appointment of Mr. Kundan Kumar Jha as Joint Company Secretary of the Company w.e.f. November 1, 2026 路 29 Oct 2026
